drugset / Trial / NCT01538849

Study to Investigate the Safety, Tolerability and Efficacy of YH4808 in Patients With Reflux Esophagitis

NCT01538849

Phase 2 Completed 154 enrolled Yuhan Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is to investigate the optimal clinical dose and administration methods of YH4808 in patients with reflux esophagitis by evaluating the safety and efficacy after YH4808 oral administration.

Timeline

Start
2012-12
Primary completion
2013-11
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Esomeprazole Small molecule 40 mg Oral
Subject YH4808 Other / unclassified Oral

Indications